Flat Is The New Up As Biogen Anticipates Stabilizing Product Revenue In 2024

EPS Will Rise, Primarily Due To Cost Cuts

 
• By Mandy Jackson

With its multiple sclerosis legacy under various pressures but four new drugs in indications outside of MS, the company expects flat product revenue in 2024 after a 3.8% decline in 2023.

Biogen sign at its headquarters in Cambridge, Massachusetts
Biogen expects lower total revenue and flat product revenue in 2024 • Source: Shutterstock

More from Business

More from Scrip